Vivani Medical Merges with ClearOne to Form Cortigent Holdings

Written by Emily J. Thompson, Senior Investment Analyst

Source: NASDAQ.COM

Updated: 4 days ago

0mins

CLRO+8.02%

Explore Agentic TradingLet AI Trade for You

Source: NASDAQ.COM

Merger Announcement: Vivani Medical's wholly owned subsidiary Cortigent is merging with ClearOne, with Cortigent becoming a wholly owned subsidiary and rebranding as Cortigent Holdings, which is set to list on Nasdaq, marking a significant milestone for Cortigent as an independent public entity.
Financing Plan: ClearOne aims to raise between $10 million and $15 million through concurrent financing, which will provide essential funding for the development of Cortigent's neurostimulation technologies, particularly in vision restoration and stroke recovery devices, thereby accelerating its technological advancements.
Equity Structure Changes: Post-merger, Vivani will receive 12.5 million shares of ClearOne common stock, expected to hold 59.4% to 67.5% of the combined entity, while former ClearOne shareholders will retain 12.7% to 14.4%, indicating Vivani's significant control in the merged company.
Market Performance: ClearOne's stock has traded between $2.71 and $12.25 over the past year, currently priced at $3.70, reflecting a 14.91% increase, indicating a positive market reaction to the merger news.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy CLRO?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on CLRO

About CLRO

ClearOne, Inc. is a global market company enabling conference, collaboration, and network streaming solutions. The Company designs, develops and sells conferencing, collaboration, and AV networking solutions for voice and visual communications. Its product categories include audio-conferencing, including installed DSP-based professional audio conferencing and USB-based speakerphones; professional microphones consisting of patented beamforming microphone arrays, ceiling microphones and wireless microphones, and video, including video collaboration and AV networking products. Its audio-conferencing products feature its proprietary HDConference, Distributed Echo Cancellation and noise cancellation technologies to enhance communication during a conference call by eliminating echo and background noise. Its professional conferencing products include the CONVERGE Pro 2 and CONVERGE Pro 2 SR product lines. Its premium conferencing offering consists of the CONVERGE Huddle product line.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

ClearOne's Strategic Shift and Merger with Cortigent

4 days agostocktwits

Strategic Pivot: ClearOne divested its legacy assets to Biamp in October last year, successfully pivoting into the medical technology sector, with former shareholders retaining approximately 12.7% to 14.4% of the new entity, indicating potential in the new market.
Reverse Merger Agreement: The announcement of a reverse merger with Cortigent, a unit of Vivani Medical, led to a more than 170% surge in CLRO stock, reflecting strong market recognition and investor optimism regarding the new business model.
Terms of the Deal: Under the agreement, Vivani will receive 12.5 million shares of ClearOne, gaining control of 59.4% to 67.5% of the combined entity, with Cortigent becoming the surviving entity, marking a new beginning for ClearOne in the medical technology field.
Funding Plan: ClearOne aims to raise up to $15 million concurrently with the deal's closing, providing a strong foundation for the combined company to advance its product pipeline and further solidify its market position.

ClearOne Signs Merger Agreement to Acquire Cortigent

4 days agoseekingalpha

Merger Agreement: ClearOne announced the signing of a definitive merger agreement to acquire Cortigent, a unit of Vivani Medical, which will become a wholly owned subsidiary post-transaction, enhancing ClearOne's competitive position in the market.
Funding Strategy: The company plans to raise $10 million to $15 million through Form S-1 financing alongside the transaction closing, with these funds expected to support the combined company's pipeline development and ensure ongoing technological innovation.
Technological Edge: Cortigent's neurostimulation technology aims to assist patients in recovering sight and motor function, addressing significant unmet medical needs, which is anticipated to provide ClearOne with new growth opportunities and market expansion.
Management Outlook: ClearOne Chairman Eric Robinson emphasized that this acquisition will help address critical health issues for patients, further solidifying the company's strategic position in the medical technology sector.